Twist in Protagonist story as FDA seeks to rescind breakthrough nod 'based on observed malignancies'

The FDA gave Protagonist Therapeutics’ rusfertide breakthrough designation last year. Now, the agency wants to take it back “based on observed malignancies,” triggering a 30% drop in Protagonist’s stock as investors scrambled to figure out the implications of the news.